- Home
- GAMB vs FATE Comparison
GAMB vs FATE Comparison
Compare GAMB & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | FATE |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 125.6M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GAMB | FATE |
|---|---|---|
| Price | $2.46 | $1.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $8.36 | $4.10 |
| AVG Volume (30 Days) | 1.2M | ★ 4.4M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $8.79 | N/A |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.23 | $0.91 |
| 52 Week High | $12.74 | $2.88 |
Technical Indicators
Market Signals| Indicator | GAMB | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 45.47 |
| Support Level | $2.23 | $1.00 |
| Resistance Level | $5.54 | $1.94 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 75.95 | 10.96 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.